Presentation is loading. Please wait.

Presentation is loading. Please wait.

Overview of the 2017 KDIGO CKD-MBD Update: Practice Implications for Adult Hemodialysis Patients  Judith Beto, PhD, RDN, FAND, Nisha Bhatt, MD, Teresa.

Similar presentations


Presentation on theme: "Overview of the 2017 KDIGO CKD-MBD Update: Practice Implications for Adult Hemodialysis Patients  Judith Beto, PhD, RDN, FAND, Nisha Bhatt, MD, Teresa."— Presentation transcript:

1 Overview of the 2017 KDIGO CKD-MBD Update: Practice Implications for Adult Hemodialysis Patients 
Judith Beto, PhD, RDN, FAND, Nisha Bhatt, MD, Teresa Gerbeling, MS, RD, CSR, Chhaya Patel, MA, RDN, CSR, Debra Drayer, PharmD  Journal of Renal Nutrition  Volume 29, Issue 1, Pages 2-15 (January 2019) DOI: /j.jrn Copyright © 2018 The Authors Terms and Conditions

2 Figure 1 Pathophysiological mechanism of chronic kidney disease-mineral bone disorders. 1,25 D, 1-α-hydroxylation of 25-hydroxy vitamin D; Ca++, ionized calcium; FGF-23, fibroblast growth factor 23; PTH, parathyroid hormone. Only change was PTH lettering to white so could be seen more clearly. Journal of Renal Nutrition  , 2-15DOI: ( /j.jrn ) Copyright © 2018 The Authors Terms and Conditions

3 Figure 2 Current SHPT therapies with complimentary effects on PTH, phosphorus, and calcium. PTH, parathyroid hormone; SHPT, secondary hyperparathyroidism. Journal of Renal Nutrition  , 2-15DOI: ( /j.jrn ) Copyright © 2018 The Authors Terms and Conditions

4 Figure 3 (Clinical Scenario Box 1). Clinical practice example for SHPT general management. CKD-MBD, chronic kidney disease-mineral bone disorder; labs, laboratory values; MBD, mineral bone disorder; prn, when necessary; PTH, parathyroid hormone; SHPT, secondary hyperparathyroidism. Journal of Renal Nutrition  , 2-15DOI: ( /j.jrn ) Copyright © 2018 The Authors Terms and Conditions

5 Figure 4 (Clinical Scenario Box 2). Clinical practice example for phosphorous and phosphate management. Journal of Renal Nutrition  , 2-15DOI: ( /j.jrn ) Copyright © 2018 The Authors Terms and Conditions

6 Figure 5 (Clinical Scenario Box 3). Clinical practice example for calcium management. CKD-MBD, chronic kidney disease-mineral bone disorder; IV, intravenous; labs, laboratory values; MBD, mineral bone disorder; QD, once a day; PTH, parathyroid hormone; SHPT, secondary hyperparathyroidism; TID, 3 times a day; TIW, 3 times a week. Journal of Renal Nutrition  , 2-15DOI: ( /j.jrn ) Copyright © 2018 The Authors Terms and Conditions

7 Figure 6 (Clinical Scenario Box 4). Clinical practice example for dialysate calcium management. CKD, chronic kidney disease; HD, hemodialysis; labs, laboratory values; TID, 3 times a day; TIW, 3 times a week. Journal of Renal Nutrition  , 2-15DOI: ( /j.jrn ) Copyright © 2018 The Authors Terms and Conditions

8 Figure 7 (Clinical Scenario Box 5). Clinical practice example for PTH management. CKD, chronic kidney disease; IV, intravenous; labs, laboratory values; PI, prescribing information; PTH, parathyroid hormone; TID, 3 times a day; TIW, 3 times a week. Journal of Renal Nutrition  , 2-15DOI: ( /j.jrn ) Copyright © 2018 The Authors Terms and Conditions


Download ppt "Overview of the 2017 KDIGO CKD-MBD Update: Practice Implications for Adult Hemodialysis Patients  Judith Beto, PhD, RDN, FAND, Nisha Bhatt, MD, Teresa."

Similar presentations


Ads by Google